Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,308 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Small Cell Lung Cancer Metastatic Clear all
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

NCT04449874
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
Interventions
GDC-6036, Atezolizumab, Cetuximab, Bevacizumab, Erlotinib, GDC-1971, Inavolisib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Duarte, California • La Jolla, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 15, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer

NCT02259582
View directory record Official record
Conditions
Nonsquamous Nonsmall Cell Neoplasm of Lung
Interventions
Pemetrexed, Carboplatin, demcizumab
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
18
States / cities
Rancho Mirage, California • San Francisco, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 15, 2026, 10:57 AM EDT
Terminated Phase 1 Interventional

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

NCT01911325
View directory record Official record
Conditions
Squamous Non-small Cell Lung Cancer
Interventions
Buparlisib, Buparlisib matching placebo, Docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Fayetteville, Arkansas • Tampa, Florida • Worcester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 15, 2026, 10:57 AM EDT
Withdrawn Phase 1 Interventional

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

NCT05693090
View directory record Official record
Conditions
NSCLC
Interventions
Tipifarnib, Osimertinib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Santa Rosa, California • Ridgewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 15, 2026, 10:57 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

NCT05403385
View directory record Official record
Conditions
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Interventions
inupadenant, Placebo, Carboplatin, Pemetrexed
Drug
Lead sponsor
iTeos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Fayetteville, Arkansas • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 15, 2026, 10:57 AM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer

NCT01820325
View directory record Official record
Conditions
Non-Small Cell Lunch Cancer
Interventions
Buparlisib, Buparlisib placebo, Carboplatin, Paclitaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Fayetteville, Arkansas • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 15, 2026, 10:57 AM EDT
Recruiting Phase 2 Interventional

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

NCT03808337
View directory record Official record
Conditions
Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma
Interventions
Stereotactic Body Radiotherapy/SBRT, Systemic Therapy/Standard of Care
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
San Carlos, California • Hartford, Connecticut • Norwalk, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 15, 2026, 10:57 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

NCT05736731
View directory record Official record
Conditions
Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
Interventions
A2B530, xT-Onco with HLA-LOH Assay
Biological · Diagnostic Test
Lead sponsor
A2 Biotherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 15, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of OSI-930 in Cancer Patients

NCT00513851
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OSI-930
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 15, 2026, 10:57 AM EDT
Terminated Phase 1 Interventional

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy

NCT04911166
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Atezolizumab and Interleukin-12 Gene Therapy
Combination Product
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 15, 2026, 10:57 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

NCT03299088
View directory record Official record
Conditions
KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Pembrolizumab, Trametinib
Biological · Drug
Lead sponsor
Jonathan Riess
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 15, 2026, 10:57 AM EDT
Terminated Phase 1 Interventional

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

NCT06974734
View directory record Official record
Conditions
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
PF-08046037, sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 15, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

NCT01336634
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
15
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 15, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

NCT03409614
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
REGN2810, REGN2810/chemo/ipi, Chemotherapy, Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
9
States / cities
Rancho Mirage, California • Riverside, California • Whittier, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 15, 2026, 10:57 AM EDT
Active, not recruiting Phase 1 Interventional

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

NCT03611738
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB, Stage IV Non-small Cell Lung Cancer, EGFR Negative Non-Small Cell Lung Cancer
Interventions
Ceritinib, Docetaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 15, 2026, 10:57 AM EDT
Recruiting No phase listed Observational

Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects

NCT06221800
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Microbiome
Diagnostic Test
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 15, 2026, 10:57 AM EDT
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

NCT04137900
View directory record Official record
Conditions
Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Interventions
TAB004, Toripalimab
Drug
Lead sponsor
TopAlliance Biosciences
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 15, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

131-I-TM-601 Study in Adults With Solid Tumors

NCT00379132
View directory record Official record
Conditions
Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Colorectal Cancer, Pancreatic Cancer, Prostate Adenocarcinoma, Glioma, Primary Solid Tumors
Interventions
131-I-TM-601 (chlorotoxin)
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2009 · Synced Oct 15, 2026, 10:57 AM EDT
Completed Phase 2 Interventional

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

NCT00030667
View directory record Official record
Conditions
Childhood Desmoplastic Small Round Cell Tumor, Childhood Synovial Sarcoma, Gastrointestinal Stromal Tumor, Lung Metastases, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
Interventions
imatinib mesylate, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 15, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

NCT02442414
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
KBP-5209
Drug
Lead sponsor
Sihuan Pharmaceutical Holdings Group Ltd.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Indianapolis, Indiana • Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 15, 2026, 10:57 AM EDT
Recruiting Not applicable Interventional

Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study

NCT05802186
View directory record Official record
Conditions
Lung Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Interventions
Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Radiology, Treatment Planning, Stereotactic Body Radiation Therapy, X-Ray Imaging
Procedure · Other · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 15, 2026, 10:57 AM EDT
Recruiting Phase 2 Interventional

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer

NCT07452224
View directory record Official record
Conditions
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
ILKN421H, Pembrolizumab
Drug
Lead sponsor
iLeukon Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 15, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)

NCT04725188
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
Pembrolizumab/Vibostolimab coformulation, Docetaxel, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Peoria, Illinois • Lexington, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 15, 2026, 10:57 AM EDT
Completed Phase 1Phase 2 Interventional

TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT00077883
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
TLK286, cisplatin
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
Baltimore, Maryland • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 15, 2026, 10:57 AM EDT